Company Valuation: Cardiol Therapeutics Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Market Cap 1 142 43.96 71.77 151 130.4 202.9 - -
Change - -69.05% 63.28% 110.34% -13.65% 55.63% - -
Enterprise Value (EV) 1 142 43.96 36.84 120.4 108.9 187.9 192.6 202.9
Change - -69.05% -16.19% 226.78% -9.5% 72.44% 2.53% 5.32%
P/E -3.19x -1.41x -2.5x -3.63x -3.36x -3.67x -7.57x 48x
PBR - - 2.55x 6.18x 6.41x 10x 18.3x -
PEG - 0x 0.2x -0.2x 0.1x -0.2x 0.1x -0x
Capitalization / Revenue 1,803x - - - - - 61.1x 5.59x
EV / Revenue 1,803x - - - - - 58x 5.59x
EV / EBITDA -4.74x -1.07x -1.25x -3x -3.18x -7.3x -12.1x -9.84x
EV / EBIT -3.67x -1.06x -1.24x -2.99x -3.17x -5.35x -7.17x 42.1x
EV / FCF -6.03x - -1.46x -4.8x -4.56x -9.25x -41.2x -
FCF Yield -16.6% - -68.5% -20.8% -21.9% -10.8% -2.43% -
Dividend per Share 2 - - - - - - - -
Rate of return - - - - - - - -
EPS 2 -0.73 -0.49 -0.44 -0.51 -0.39 -0.48 -0.2325 0.0367
Distribution rate - - - - - - - -
Net sales 1 0.0788 - - - - - 3.321 36.32
EBITDA 1 -29.95 -41.12 -29.54 -40.11 -34.21 -25.72 -15.88 -20.62
EBIT 1 -38.66 -41.34 -29.79 -40.28 -34.32 -35.09 -26.87 4.821
Net income 1 -31.64 -30.93 -28.13 -36.68 -33.82 -35.21 -30.57 -8.68
Net Debt 1 - - -34.93 -30.58 -21.42 -15.01 -10.26 -
Reference price 2 2.330 0.690 1.100 1.850 1.310 1.760 1.760 1.760
Nbr of stocks (in thousands) 60,954 63,703 65,247 81,603 99,514 115,272 - -
Announcement Date 23/03/22 28/03/23 01/04/24 31/03/25 31/03/26 - - -
1CAD in Million2CAD
Estimates

P/E, Detailed evolution

P/E (N) EV / Sales (N) EV / EBITDA (N) Dividend Yield (N) Capi.($)
-3.67x - -7.3x - 145M
32.83x5.9x17.55x0.98% 48.53B
-23.41x351.08x-21.45x-.--% 39.87B
30.42x3.04x13.11x-.--% 38.68B
46.94x4.76x30.78x-.--% 35.13B
28.41x8.22x20.66x0.41% 29.79B
32.82x5.37x24.39x-.--% 16.11B
22.67x1.99x8.61x1.17% 13.61B
25.33x1.86x11.4x-.--% 12.62B
Average 21.37x 47.78x 10.86x 0.32% 26.05B
Weighted average by Cap. 23.41x 63.80x 12.17x 0.32%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Stocks
  3. CRDL Stock
  4. Valuation Cardiol Therapeutics Inc.